-Dragonfly Therapeutics anuncia la presentación de la fase 1 de los resultados del aumento de dosis de DF1001 TriNKET® en la reunión anual de ASCO 2023 En la Sesión de Terapéutica del Desarrollo – Inmunoterapia de ASCO, el Dr. Howard Safran presenta datos alentadores sobre el estudio de…
This website uses cookies so that we can provide you with the best user experience possible. Cookie information is stored in your browser and performs functions such as recognising you when you return to our website and helping our team to understand which sections of the website you find most interesting and useful.